$Elevai Labs (ELAB.US)$ Elevai Labs Inc. reported strong fin...

$Elevai Labs (ELAB.US)$ Elevai Labs Inc. reported strong financial results for Q2 2024, with a notable 74.7% gross margin, despite a slight drop in revenue for the quarter compared to the previous year. The company successfully raised $8 million through a public offering to further its growth strategies. Elevai is advancing its clinical initiatives, particularly with the Elevai Enfinity skin treatment, which demonstrated improvements in skin firmness and wrinkle reduction, and is expanding its patent portfolio with EL-22, a new obesity treatment targeting myostatin to aid muscle preservation. Additionally, Elevai's partnership with other research organizations has led to promising developments in both skin health and hair restoration technologies.